X0202 4/A 2007-07-09 2007-07-11 0 0001060736 SEATTLE GENETICS INC /WA SGEN 0001106607 JP MORGAN PARTNERS BHCA LP J.P. MORGAN PARTNERS 270 PARK AVENUE NEW YORK NY 10017 0 0 1 0 0001243235 JPMP MASTER FUND MANAGER L P JPMORGAN PARTNERS LLC 270 PARK AVENUE NEW YORK NY 10017 0 0 1 0 0001330534 JPMP CAPITAL CORP J.P. MORGAN PARTNERS, LLC 270 PARK AVENUE NEW YORK NY 10017 0 0 1 0 0001162622 JP MORGAN PARTNERS GLOBAL INVESTORS LP J.P. MORGAN PARTNERS, LLC 270 PARK AVENUE NEW YORK NY 10017 1 0 0 0 0001169890 J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP J.P. MORFAN PARTNERS, LLC 270 PARK AVENUE NEW YORK NY 10017 1 0 0 0 0001169889 J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP J P MORGAN PARTNERS 270 PARK AVENUE NEW YORK NY 10017 0 0 1 0 0001317638 JP MORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP JP MORGAN PARTNERS, LLC 270 PARK AVENUE NEW YORK NY 10017 0 0 1 0 Class A Common Stock 2007-07-09 4 C 0 2263980 A 2263980 D Class A Common Stock 2007-07-09 4 C 0 559850 A 559850 I See Footnote Class A Common Stock 2007-07-09 4 C 0 284160 A 284160 I See Footnote Class A Common Stock 2007-07-09 4 C 0 76320 A 76320 I See Footnote Class A Common Stock 2007-07-09 4 C 0 31660 A 31660 I See Footnote Class A Common Stock 2007-07-09 4 C 0 210390 A 210390 I See Footnote Class A Common Stock 2007-07-09 4 C 0 1058640 A 1058640 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 469594 469594 D Warrants 6.25 2003-07-08 2011-12-31 Common Stock 101421 101421 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 13826 13826 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 51478 51478 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 5736 5736 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 38114 38114 I See Footnote Warrants 6.25 2003-07-08 2011-12-31 Common Stock 132331 132331 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 226398 D 2004-07-08 Common Stock 2263980 0 D Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 55985 D 2004-07-08 Common Stock 559850 0 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 28416 D 2004-07-08 Common Stock 284160 0 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 7632 D 2004-07-08 Common Stock 76320 0 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 3166 D 2004-07-08 Common Stock 31660 0 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 21039 D 2004-07-08 Common Stock 210390 0 I See Footnote Series A Convertible Preferred Stock 2.50 2007-07-09 4 C 0 105864 D 2004-07-08 Common Stock 1058640 0 I See Footnote Stock Options (Right to Purchase) 7.26 2005-05-16 2014-05-16 Common Stock 10000 10000 I See Footnote Stock Options (Right to Purchase) 5.11 2006-05-12 2015-05-12 Common Stock 10000 10000 I See Footnote Stock Options (Right to Purchase) 10.20 2008-05-24 2017-05-25 Common Stock 10000 10000 I See Footnote The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P. The Reporting Person has no pecuniary interest in such securities. The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P. The Reporting Person has no pecuniary interest in such securities. The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P. The Reporting Person has no pecuniary interest in such securities. The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P. The Reporting Person has no pecuniary interest in such securities. The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown), L.P. The Reporting Person has no pecuniary interest in such securities. The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Selldown II), L.P. The Reporting Person has no pecuniary interest in such securities. The conversion price of the Series A Convertible Preferred Stock is equal to the initial purchase price divided by $2.50, as adjusted for stock splits, stock dividends, combinations and other similar capitalizations of the Issuer's Common and Preferred Stock. Initially this results in a 1 for 10 conversion ratio. Each share of Series A Convertible Preferred Stock is entitled to 0.93 votes for each share of Common Stock into which such share of Convertible Preferred Stock could then be converted. All outstanding shares of the Issuer's Series A Convertible Preferred Stock are convertible at the holder's option into shares of the Issuer's Common Stock on a 10 to 1 basis any time after July 8, 2004. This right to convert does not expire. These options were granted to Srinivas Akkaraju, a director of the Issuer. Mr. Akkaraju is obligated to transfer any shares issued under the Stock Option to J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA") at the request of JPM BHCA. N/A. This filing is being amended to correct the amount of securities beneficially owned in Table I, Row 4, Box 5 which were previously reported as 79,320. The correct amount is 76,320. This filing is being amended to correct the dates in Table II, Rows 8-14, Box 3. The dates listed on the filing previously submitted on 7/11/2007 were 2/9/2007. The correct dates are 7/9/2007. This filing is being amended to correct the name of the issuer in Box 2, listed on the issuer's filing on 7/11/2007 as J.P. Morgan Partners Global, L.P. The issuer's correct name is "Seattle Genetics, Inc." /s/ J.P. Morgan Partners (BHCA), L.P., By: JPMP Master Fund Manager, L.P., its general partner, By: JPMP Capital Corp., its general partner, By: John C. Wilmot 2007-07-12